Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01579994 · ClinicalTrials.gov registry record · Phase 1
Crizotinib and Ganetespib (STA-9090) in ALK Positive Lung Cancers
A Phase 1 study, sponsored by Memorial Sloan Kettering Cancer Center.
- Completed
- Registry status
- Phase 1
- Development phase
- 13
- Enrollment target
NCT01579994: Completed Phase 1 study, sponsored by Memorial Sloan Kettering Cancer Center.
NCT01579994 is a Phase 1 study that has completed, run by Memorial Sloan Kettering Cancer Center. The registered enrollment target is 13 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01579994, a Phase 1 study, has completed, sponsored by Memorial Sloan Kettering Cancer Center.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 13 participants
- Enrollment target
Study Summary
About 18 patients will take part in the phase 1 portion of the trial. In the beginning of the study, 3 patients will be treated with a low dose of ganetespib (STA-9090) and the standard dose of crizotinib. If this dose does not cause significant side effects, it will be increased as new patients take part in the study. The study will only be open at Memorial Sloan Kettering Cancer Center.
Interventions
- DRUG Ganetespib (STA-9090) and crizotinib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 13 participants |
| Start Date | 2012-04-16 |
| Est. Completion | 2020-12-28 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01579994
The ClinicalTrials.gov registry entry for NCT01579994 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 13 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Memorial Sloan Kettering Cancer Center, which has 1,884 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Ganetespib (STA-9090) and crizotinib is the first listed.
NCT01579994 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01579994 about?
NCT01579994 is a clinical study titled "Crizotinib and Ganetespib (STA-9090) in ALK Positive Lung Cancers". About 18 patients will take part in the phase 1 portion of the trial. In the beginning of the study, 3 patients will be treated with a low dose of ganetespib (STA-9090) and the standard dose of crizotinib. If this dose does not cause significant side effects, it will be increased as new patients tak...
What is the current status of trial NCT01579994?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 13 participants. The study started on 2012-04-16. Estimated completion is 2020-12-28.
What interventions are being tested in trial NCT01579994?
The interventions under investigation include: Ganetespib (STA-9090) and crizotinib (DRUG).
Who is sponsoring clinical trial NCT01579994?
This trial is sponsored by Memorial Sloan Kettering Cancer Center, which has 1,884 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.